Clinical Trials

132 enrolled

CNS

Glioma

NCT07416188 2026-04-22

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

40 enrolled

CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, Recurrence, Central Nervous System Neoplasms

NCT06287775 2026-04-21

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

45 enrolled

Thoracic

Lung Neoplasms

NCT03942328 2026-04-20

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

85 enrolled

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT07147231 2026-04-20

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

86 enrolled

Colorectal Neoplasms

NCT07437963 2026-04-15

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

76 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT05232851 2026-04-14

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

20 enrolled 11 charts

Head & Neck

Carcinoma, Oropharyngeal Neoplasms

NCT06965114 2026-04-14

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Other hematologic neoplasm

84 enrolled

Leukemia, Hairy Cell

NCT01989585 2026-04-13

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

75 enrolled

Dermatologic

Melanoma

NCT04068194 2026-04-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

103 enrolled

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT04172532 2026-04-13

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

92 enrolled

Pancreatic Neoplasms

NCT04317105 2026-04-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

54 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04345913 2026-04-13

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

24 enrolled 24 charts

Breast

Triple Negative Breast Neoplasms

NCT05019716 2026-04-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

36 enrolled

Advanced NUT Carcinoma

NCT05691491 2026-04-13

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

58 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT05896839 2026-04-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

16 enrolled

Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT06498648 2026-04-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

74 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT06616155 2026-04-13

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

39 enrolled

Genitourinary

Prostatic Neoplasms

NCT07012031 2026-04-13

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07069699 2026-04-13

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

50 enrolled

Lymphoid

Burkitt Lymphoma

NCT07463807 2026-04-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

162 enrolled

Plasma cell

Multiple Myeloma

NCT05920798 2026-04-06

FRAPPE

40 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07225985 2026-04-03

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

50 enrolled

Lymphoid

Lymphoma, T-Cell

NCT04557956 2026-04-02

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment

16 enrolled

Dermatologic

Melanoma

NCT07181941 2026-03-27

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma